Many posters have commented that Imugene is relatively unknown...

Many posters have commented that Imugene is relatively unknown in Australia and almost unknown on the world Biotech stage. On the flip side, Professor Yuman Fong is widely acclaimed and simply world famous (to put it in simple terms). Is it possible for Management and the Board to do what they can to attach the two together in presentations, announcements etc. He gets rave reviews for his work, and deservedly so, but Imugene gets none?

I appreciate so much the great medical/scientific/strategic opinions of our many brilliant posters, However I have almost nil medical knowledge other than what has been absorbed from my cancer struggles over the years. So the above comments are about all I can contribute. Meanwhile I continue to be very positive about Imugene"s prospects for both shareholders and patients.